← Back to Search

Exercise Training for Heart Failure

N/A
Recruiting
Led By Bryan J Taylor, PhD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinically-stable for > 3 months [no change in disease status or medication]
NYHA functional class I-IIIb
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 weeks
Awards & highlights

Study Summary

This trial is testing if exercise therapy can help improve the heart function, overall health, and quality of life of patients with pulmonary hypertension caused by heart failure.

Who is the study for?
This trial is for heart failure patients with reduced heart function (LVEF < 40%) who've been stable for over 3 months and can exercise on a bike or treadmill. It's not for those in the most severe stage of heart failure, pregnant women, individuals with certain other health issues like severe obesity or uncontrolled diabetes, or conditions that limit exercise.Check my eligibility
What is being tested?
The study is testing if regular exercise can improve how well the heart works, overall health, and life quality in people with pulmonary hypertension due to heart failure. Participants will follow an exercise program using bikes or treadmills.See study design
What are the potential side effects?
Exercise training may lead to general discomforts such as muscle soreness, fatigue, shortness of breath during activity, and increased risk of falls or injuries related to physical activity.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My health condition has been stable for over 3 months.
Select...
My heart condition allows me to perform daily activities with slight to moderate limitations.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximal oxygen uptake (VO2max) measured in mL/kg/min
Secondary outcome measures
Left ventricular contractile function measured as % fractional area change (LV FAC).
Mean pulmonary arterial pressure (mPAP) measured in mmHg
Pulmonary vascular resistance (PVR) measured in dynes
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Exercise TrainingExperimental Treatment1 Intervention
Two sets of exercise testing (before and after) 10 weeks of supervised exercise training (3 sessions per week) at Mayo Clinic Florida.
Group II: Control GroupsActive Control1 Intervention
Two sets of exercise testing while continuing with standard medical care in between.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,191 Previous Clinical Trials
3,758,471 Total Patients Enrolled
Florida Heart Research InstituteOTHER
2 Previous Clinical Trials
180 Total Patients Enrolled
Bryan J Taylor, PhDPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
40 Total Patients Enrolled

Media Library

Pulmonary Hypertension Clinical Trial 2023: Exercise Training Highlights & Side Effects. Trial Name: NCT04909008 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are partaking in this medical research?

"Affirmative. Clinicaltrials.gov data reveals that this study, which was initially posted on March 1st 2023 is currently enrolling participants. 40 individuals will be accepted into the trial at a single site."

Answered by AI

Are there any opportunities available to enroll in this research endeavor?

"Affirmative. Information from clinicaltrials.gov verifies that this medical trial is actively recruiting subjects, with 40 participants desired at 1 location since its inception on March 1st 2023 and last update on November 10th 2022."

Answered by AI
~27 spots leftby Aug 2025